Nexentis Technologies (NXTS) Research & Development (2019 - 2026)
Nexentis Technologies (NXTS) posted Research & Development of $373000.0 for Q2 2026, up 661.22% on a QoQ basis from $49000.0 in Q4 2025, and up 661.22% year-over-year from $49000.0 in Q2 2025.
Powered by 
Analysis
Nexentis Technologies (NXTS) Research & Development (2019 - 2026) Analysis & Trends
Nexentis Technologies has reported Research & Development for 8 years, with the latest figure at $373000.0 in Q2 2026.
- On a quarterly basis, Research & Development rose 661.22% year-over-year to $373000.0 in Q2 2026; TTM through Jun 2026 was $523000.0, a 49.0% increase from a year earlier, with the FY2025 full-year figure at $179000.0, down 51.49% from the prior year.
- Research & Development was $373000.0 for Q2 2026 at Nexentis Technologies, up from $49000.0 in the prior quarter.
- The five-year high for Research & Development was $1.7 million in Q3 2023, with the low at $47000.0 in Q1 2025.
- Average Research & Development over 5 years is $224134.2, with a median of $116000.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Research & Development surged 753.0% in 2023, then slumped 96.16% in 2024.
- Over 5 years, Research & Development stood at $249587.0 in 2022, then sank by 56.32% to $109030.0 in 2023, then soared by 74.26% to $190000.0 in 2024, then plunged by 74.21% to $49000.0 in 2025, then soared by 661.22% to $373000.0 in 2026.
- The last three Research & Development figures came in at $373000.0 (Q2 2026), $49000.0 (Q4 2025), and $52000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Nexentis Technologies | 1.40 Mn | -7.48 Mn | - | 373,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 373,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Sep 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Dec 31, 2023 | 109,030.00 |
| Sep 30, 2023 | 1.69 Mn |
| Jun 30, 2023 | 88,775.00 |
| Mar 31, 2023 | 118,908.00 |
| Dec 31, 2022 | 249,587.00 |
| Sep 30, 2022 | 198,501.00 |
| Jun 30, 2022 | 144,913.00 |
| Mar 31, 2022 | 209,362.00 |
| Dec 31, 2021 | 175,681.00 |
| Sep 30, 2021 | 69,019.00 |
| Jun 30, 2021 | 226,742.00 |